A new law will allow Providence Tarzana Medical Center to request an additional extension from the California Hospital Seismic Safety Act.
Second Sight Medical Products Inc. will conduct a clinical study in Germany to evaluate Argus II, its retinal prosthetic system, the company has announced.
MannKind Corp. on Wednesday announced that the company is offering approximately 10.6 million shares to certain investors in an effort to raise $61 million.
Riding the momentum of last week’s gains, MannKind Corp. closed up again more than 25 percent Tuesday.
Conejo Valley’s senior biotech executives discussed why they put down roots in the region at the BioScience Alliance’s Panel Event on Wednesday in Thousand Oaks.
Two Valley eldercare facilities have traded hands as part of a $378 million portfolio to an Orange County health care property owner.
California State University – Northridge and Dignity Health Northridge Hospital Medical Center have entered a health partnership, the school has announced.
Amgen Inc. today announced that it has entered into a strategic collaboration in immune-oncology with CytomX Therapeutics Inc. in San Francisco.
Following a 7 percent increase Monday, shares of MannKind Corp. stayed bullish, closing up more than 20 percent increase on Tuesday.
Simulations Plus Inc. released preliminary results for its fiscal fourth quarter and fiscal 2017, saying that it’s the last time it will release results prior to officially filings with the Securities and Exchange Commission.
MannKind Corp. today announced that the U.S. Food & Drug Administration has updated prescribing information for Afrezza, the company’s sole commercial product.
Investment bank FBR Capital Markets & Co. has hired four analysts to cover the health care, pharmaceutical, medical devices and diagnostics industries.
Amgen Inc.’s Amjevita, a biosimilar of the bestselling drug in the world, will launch in Europe and the United States in 2018 and 2023, respectively, the company announced.
Amgen Inc. on Tuesday announced an exclusive agreement with Simcere Pharmaceutical Group to co-develop and commercialize four biosimilar drugs in China.